10h
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
Bayer (BAYZF) stock is in focus as the FDA grants accelerated approval for the company's tumor drug Hyrnuo in non-squamous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback